(18.207.240.230) 您好!臺灣時間:2020/07/09 10:49
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
本論文永久網址: 
line
研究生:高嘉靖
研究生(外文):Jia-jing Gau
論文名稱:青光眼病患併發糖尿病,使用Metformin及Sulfonylurea治療得到中風之風險:以台灣人口為基礎的觀察性研究
論文名稱(外文):Risk of stroke in glaucoma patients with diabetes treated with metformin and sulfonylurea: A population-based observational study in Taiwan
指導教授:洪炯宗
指導教授(外文):Jorng-Tzong Horng
學位類別:碩士
校院名稱:國立中央大學
系所名稱:資訊工程學系
學門:工程學門
學類:電資工程學類
論文出版年:2015
畢業學年度:103
語文別:中文
論文頁數:32
中文關鍵詞:中風青光眼糖尿病
外文關鍵詞:strokeglaucomadiabetes
相關次數:
  • 被引用被引用:0
  • 點閱點閱:93
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
中風在已開發國家中是造成死亡和殘疾的主要原因排名第二。並為國家醫療保健系統帶來沉重負擔,糖尿病是青光眼的常見合併症,這兩種疾病都是中風的已知危險因素,且這兩種疾病在全球的盛行率越來越高。在近年研究中,有許多青光眼對於中風的風險影響和中風在糖尿病患者的風險的一些研究。然而,對於青光眼患者同時患有糖尿病是否會增加中風的風險和糖尿病藥物Metformin及Sulfonylurea對於青光眼病人同時患有糖尿病的治療效果的長期追蹤研究尚未有人提出。為了研究這個議題,我們使用了台灣全民健康保險研究數據庫(NHIRD)評估青光眼患者併發糖尿病對於中風風險的影響,同時研究在這些患者中兩種糖尿病藥物的治療效果。
Stroke is the second most common cause of death and a primary source of disability in developed countries. And it becomes a heavy burden on national healthcare systems. Diabetes is a common comorbidity of glaucoma, and these two diseases are both risk factor of stroke. In recent years, there are some studies about the effect of stroke in glaucoma patients and the risk of stroke in diabetes patients. However, there still no long-term studies about whether glaucoma patients with diabetes will increase the risk of Stroke and the effect of diabetes treatments in glaucoma patients with diabetes. To address this issue, we used the Taiwan National Health Insurance Research Database (NHIRD) evaluate the stroke effect of in glaucoma patients with previous diabetes compared to only glaucoma patients, and we also evaluate the risk of stroke in these patients treated with Metformin and Sulfonylurea.
Table of Contents
摘要 i
ABSTRACT ii
List of Tables iv
List of Figures iv
Chapter 1 Introduction 1
1.1 Background 1
1.2 Motivation 3
1.3 Research Goal 3
Chapter 2 Related Works 4
2.1 Glaucoma and Stroke 4
2.2 Diabetes and stroke 4
2.3 Diabetes and Metformin /Sulfonylurea 5
Chapter 3 Methods 6
3.1 Data Source 6
3.2 Study Design 6
3.3 Comorbidities and CCI 8
3.4 Statistical analysis 8
Chapter 4 Results 11
4.1 Baseline Characteristics 11
4.2 Stroke Rate 14
4.3 Risk of Stroke 16
4.4 Kaplan-Meier Stroke-Free Curves 18
Chapter 5 Discussion and Conclusion 19
References: 22

List of Tables
Table 1. ICD-9-CM codes of diseases and comorbidities 9
Table 2. ICD-9-CM and score of Charlson comorbidity index 10
Table 3. Demographic characteristics of glaucoma patients 12
Table 4. Risk of stroke among glaucoma patients with diabetes drug used of without diabetes drug used 15
Table 5. Crude and adjusted HR of stroke associated with diabetes drug used among glaucoma patients 17

List of Figures
Figure 1. Flow Chart of Study Design 7
Figure 2. Kaplan-Meier Stroke-Free Curves 18

1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004 May 22;363(9422):1711–20
2. Lin, I-Chan, et al. "Glaucoma, Alzheimer's Disease, and Parkinson's Disease: An 8-Year Population-Based Follow-Up Study." (2014): e108938.
3. Jørgensen, H., et al. "Stroke in patients with diabetes. The Copenhagen Stroke Study." Stroke 25.10 (1994): 1977-1984. [14]
4. Chen, Hung-Lin, and Fei-Yuan Hsiao. "Risk of hospitalization and healthcare cost associated with Diabetes Complication Severity Index in Taiwan's National Health Insurance Research Database." Journal of Diabetes and its Complications 28.5 (2014): 612-616.
5. Amos AF, McCarty DJ, Zimmet P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 (Suppl. 5):S1–S85, 1997
6. Asfandiyarova, Nailya, et al. "Risk factors for stroke in type 2 diabetes mellitus." Diabetes and Vascular Disease Research 3.1 (2006): 57.
7. Lin, Herng-Ching, et al. "Urbanization and stroke prevalence in Taiwan: analysis of a nationwide survey." Journal of Urban Health 84.4 (2007): 604-614.
8. Baliga, Bantwal Suresh, and Jesse Weinberger. "Diabetes and stroke: part one—risk factors and pathophysiology." Current cardiology reports 8.1 (2006): 23-28.
9. Wolf, Philip A., et al. "Probability of stroke: a risk profile from the Framingham Study." Stroke 22.3 (1991): 312-318.
10. Ho, Jau-Der, Chao-Chien Hu, and Herng-Ching Lin. "Open-Angle Glaucoma and the Risk of Stroke Development A 5-Year Population-Based Follow-Up Study." Stroke 40.8 (2009): 2685-2690.
11. French, Dustin D., and Curtis E. Margo. "Open Angle Glaucoma and Stroke." Ophthalmology 117.8 (2010): 1653-e3.
12. Ottenbacher, Kenneth J., et al. "Diabetes mellitus as a risk factor for stroke incidence and mortality in Mexican American older adults." The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59.6 (2004): M640-M645.
13. Zakikhani, Mahvash, et al. "Metformin is an AMP kinase–dependent growth inhibitor for breast cancer cells." Cancer research 66.21 (2006): 10269-10273.
14. Stolar, Mark W., et al. "Managing type 2 diabetes: going beyond glycemic control." Journal of Managed Care Pharmacy 14.5 (2008).
15. Bowker, S. L., et al. "Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure." Diabetologia 53.8 (2010): 1631-1637.
16. DeFronzo, Ralph A. "Pharmacologic therapy for type 2 diabetes mellitus." Annals of internal medicine 131.4 (1999): 281-303.
17. Kendall, David M., et al. "Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea." Diabetes care 28.5 (2005): 1083-1091.
18. D'Hoore, William, André Bouckaert, and Charles Tilquin. "Practical considerations on the use of the Charlson comorbidity index with administrative data bases." Journal of clinical epidemiology 49.12 (1996): 1429-1433.
19. Hsu, Chih-Cheng, et al. "Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin." Journal of Alzheimer's disease: JAD 24.3 (2010): 485-493.
20. Johnson, Jeffrey A., et al. "Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes." Diabetes care 25.12 (2002): 2244-2248.
21. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339, b4731.
22. Olsson, J., et al. "Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study." Diabetologia 43.5 (2000): 558-560.
23. Uwaifo GI, Ratner RE. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol. 2007;99:51B-67B.
24. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29:1963-72.

連結至畢業學校之論文網頁點我開啟連結
註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔